Generic Name and Formulations:
Oxybutynin 3.9mg/day; transdermal patch.
Indications for OXYTROL:
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Apply to clean, dry area on the abdomen, hip, or buttock. 1 patch twice weekly (every 3–4 days). Rotate application sites.
Urinary or gastric retention, uncontrolled narrow-angle glaucoma; or patients at risk for these.
Bladder outflow or GI obstruction. Hepatic or renal impairment. Ulcerative colitis. Intestinal atony. Hiatus hernia/GERD. Discontinue if skin hypersensitivity or angioedema develops; consider discontinuing if anticholinergic CNS effects occur. Avoid in myasthenia gravis; discontinue if symptoms occur. Exposure to high environmental temperature. Pregnancy. Nursing mothers.
CNS depression potentiated by alcohol, other CNS depressants. Additive effects with other anticholinergics. May affect GI absorption of other drugs. Caution with drugs that cause or exacerbate esophagitis (eg, bisphosphonates).
Local reactions, anticholinergic effects (eg, dry mouth, constipation, dizziness, abnormal vision, somnolence, confusion, hallucinations), headache, diarrhea, rash.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy